Home LiteratureArticle Details
PMID: 20421500 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Genetic control of mammalian T-cell proliferation with synthetic RNA regulatory systems.

Chen YY, Jensen MC, Smolke CD

Abstract

RNA molecules perform diverse regulatory functions in natural biological systems, and numerous synthetic RNA-based control devices that integrate sensing and gene-regulatory functions have been demonstrated, predominantly in bacteria and yeast. Despite potential advantages of RNA-based genetic control strategies in clinical applications, there has been limited success in extending engineered RNA devices to mammalian gene-expression control and no example of their application to functional response regulation in mammalian systems. Here we describe a synthetic RNA-based regulatory system and its application in advancing cellular therapies by linking rationally designed, drug-responsive, ribozyme-based regulatory devices to growth cytokine targets to control mouse and primary human T-cell proliferation. We further demonstrate the ability of our synthetic controllers to effectively modulate T-cell growth rate in response to drug input in vivo. Our RNA-based regulatory system exhibits unique properties critical for translation to therapeutic applications, including adaptability to diverse ligand inputs and regulatory targets, tunable regulatory stringency, and rapid response to input availability. By providing tight gene-expression control with customizable ligand inputs, RNA-based regulatory systems can greatly improve cellular therapies and advance broad applications in health and medicine.

MeSH Terms
Animals Cell Line Cell Proliferation Cell Survival Gene Expression Regulation Genetic Engineering/methods Humans Interleukin-15/metabolism Mammals/metabolism Mice Pharmaceutical Preparations RNA, Catalytic/metabolism T-Lymphocytes/cytology Time Factors
Chemicals
Interleukin-15 Pharmaceutical Preparations RNA, Catalytic
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Chen Yvonne Y
Division of Chemistry and Chemical Engineering, California Institute of Technology, Pasadena, CA 91125, USA.
Jensen Michael C
Smolke Christina D
References (30)
30 references, click to expand
  1. Prediction of RNA secondary structure by free energy minimization.
    Curr Opin Struct Biol. 2006 Jun;16(3):270-8 PMID: 16713706
  2. Design principles for riboswitch function.
    PLoS Comput Biol. 2009 Apr;5(4):e1000363 PMID: 19381267
  3. Contrasting roles of IL-2 and IL-15 in the life and death of lymphocytes: implications for immunotherapy.
    Immunity. 2001 Feb;14(2):105-10 PMID: 11239443
  4. Long term culture of tumour-specific cytotoxic T cells.
    Nature. 1977 Jul 14;268(5616):154-6 PMID: 145543
  5. Adoptive immunotherapy for cancer: building on success.
    Nat Rev Immunol. 2006 May;6(5):383-93 PMID: 16622476
  6. Pharmacologically regulated in vivo selection in a large animal.
    Blood. 2002 Sep 15;100(6):2026-31 PMID: 12200362
  7. High-resolution molecular discrimination by RNA.
    Science. 1994 Mar 11;263(5152):1425-9 PMID: 7510417
  8. Cancer regression in patients after transfer of genetically engineered lymphocytes.
    Science. 2006 Oct 6;314(5796):126-9 PMID: 16946036
  9. Cytotoxic T-lymphocyte (CTL) responses against acute or chronic myeloid leukemia.
    Immunol Rev. 1997 Jun;157:223-30 PMID: 9255633
  10. Higher-order cellular information processing with synthetic RNA devices.
    Science. 2008 Oct 17;322(5900):456-60 PMID: 18927397
  11. Engineered riboregulators enable post-transcriptional control of gene expression.
    Nat Biotechnol. 2004 Jul;22(7):841-7 PMID: 15208640
  12. Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells.
    Cancer Res. 2004 Dec 15;64(24):9160-6 PMID: 15604287
  13. Frameworks for programming biological function through RNA parts and devices.
    Chem Biol. 2009 Mar 27;16(3):298-310 PMID: 19318211
  14. Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy.
    J Immunol. 2004 Dec 15;173(12):7125-30 PMID: 15585832
  15. Improving T cell therapy for cancer.
    Annu Rev Immunol. 2007;25:243-65 PMID: 17129181
  16. Complex riboswitches.
    Science. 2008 Mar 28;319(5871):1795-7 PMID: 18369140
  17. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells.
    Proc Natl Acad Sci U S A. 2002 Dec 10;99(25):16168-73 PMID: 12427970
  18. Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates.
    J Clin Invest. 2008 Jan;118(1):294-305 PMID: 18060041
  19. Principles of adoptive T cell cancer therapy.
    J Clin Invest. 2007 May;117(5):1204-12 PMID: 17476350
  20. RNA synthetic biology.
    Nat Biotechnol. 2006 May;24(5):545-54 PMID: 16680139
  21. Primary human T lymphocytes engineered with a codon-optimized IL-15 gene resist cytokine withdrawal-induced apoptosis and persist long-term in the absence of exogenous cytokine.
    J Immunol. 2005 Dec 1;175(11):7226-34 PMID: 16301627
  22. The RNAi revolution.
    Nature. 2004 Jul 8;430(6996):161-4 PMID: 15241403
  23. A tetracycline-binding RNA aptamer.
    Bioorg Med Chem. 2001 Oct;9(10):2549-56 PMID: 11557342
  24. A modular and extensible RNA-based gene-regulatory platform for engineering cellular function.
    Proc Natl Acad Sci U S A. 2007 Sep 4;104(36):14283-8 PMID: 17709748
  25. In vitro selection of functional nucleic acids.
    Annu Rev Biochem. 1999;68:611-47 PMID: 10872462
  26. A proliferation switch for genetically modified cells.
    Proc Natl Acad Sci U S A. 1997 Apr 1;94(7):3076-81 PMID: 9096348
  27. The catalytic diversity of RNAs.
    Nat Rev Mol Cell Biol. 2005 May;6(5):399-412 PMID: 15956979
  28. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor.
    N Engl J Med. 1995 Oct 19;333(16):1038-44 PMID: 7675046
  29. Tyrosine phosphorylation and activation of STAT5, STAT3, and Janus kinases by interleukins 2 and 15.
    Proc Natl Acad Sci U S A. 1995 Sep 12;92(19):8705-9 PMID: 7568001
  30. Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma.
    J Clin Oncol. 2006 Nov 1;24(31):5060-9 PMID: 17075125
Article Info
Journal
Proceedings of the National Academy of Sciences of the United States of America
Abbr.
Proc Natl Acad Sci U S A
ISSN
1091-6490
Published
2010-05-11
Epub
2010-00-26
Pages
8531-6
Language
English
Region
United States
NLM ID
7505876
PMCID
PMC2889348
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com